Diasorin S.p.a Stock News

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

(RTTNews) - QIAGEN (QGEN) and DiaSorin said Monday that the U.S. Food and Drug Administration has approved the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin''s automated LIAISON XS platform. The company noted that the approval widens the accessibility of U.S. customers to automation solutions for processing QIAGEN''s blood-based test

Additional U.S. approval for LIAISON XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin''s LIAISON XL analyzer Collaboration now provides full range of automation

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has a

Black Friday Turns Red On "Terrible News" - Global Markets Crater On "Nu Variant" Panic The Friday after thanksgiving is called black Friday because that''s when retailers finally turn profitable for the year. Not so much for market, however, because this morning it''s red as far as the eye can see. The culprit: the same one we discussed late last night - the emergence of a new coronavirus strain detected in South Africa, known as B.1.1.529, which reportedly carries an "extremely high number" of mutations and is “clearly very different” from previous incarnations, which may drive further waves of disease by evading the body’s defenses according to South African scientists, and soon, Anthony Fauci. British authorities think it is the most significant variant to date and have hurried to impose travel restrictions on southern Africa, as did Japan, the Czech Republic and Italy on Friday. The European Union also said it aimed to halt air travel from the region. "Markets have been quite complacent about the pandemic for a while, partly because economies have been able to withstand the impact of selective lockdown measures.

The Diagnostic Tests report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2028. The data included

Kepler Capital Markets lowered shares of DiaSorin (OTCMKTS:DSRLF) from a buy rating to a hold rating in a report published on Wednesday, Briefing.com reports. Other research analysts have also issued reports about the stock. Morgan Stanley assumed coverage on shares of DiaSorin in a research note on Tuesday, July 27th. They issued an equal weight []

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2021 Results - Earnings Call Transcript

DiaSorin is a world leader in the sale of reagents to laboratories. It converts about 25-30% of its revenue into free cash flow.

Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX) for $37 per share in an all-cash transaction, corresponding to a total equity value

Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. for around $1.8 billion. DiaSorin will pay $37 for each sha

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2020 Results - Earnings Call Transcript

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

According to the High Quality Screener, a Premium All-in-One Screener template, five high-quality stocks based in Mediterranean countries are Diasorin SpA (MIL:DIA), Koza Altin Izletmeleri AS (IST:KOZ